BFS Molecular provides a new breed of post-transplant monitoring tests, offering novel approaches and a higher quality of results than anything available today.  

Earlier detection of an adverse event provides more treatment options for the physician, potentially allowing transplant rejection or disease relapse to be avoided altogether.  This leads to improved outcomes for many transplantation patients, and saves significant costs for national health bodies and insurance companies. 

As a secondary goal, BFS Molecular has adopted an integrated approach to monitoring, offering a single software package covering the whole continuum of post-transplant testing - providing streamlined workflows in transplantation testing labs and saving time, effort and money.